In the News
Meta-analysis quantifies survival gains from bariatric surgery
According to an analysis of studies of severely obese patients, metabolic-bariatric surgery was associated with median life expectancy gains of 9.3 years in patients with diabetes and 5.1 years in patients without diabetes.
More guideline-recommended diabetes care provided to older U.S. adults, not other age groups
From 2005 to 2018, the proportion of diabetes patients receiving care as recommended by the American Diabetes Association increased from 29.3% to 44.2% among those ages 65 years or older but did not change significantly for those ages 40 to 64 years (25.2% to 25.8%) or 20 to 39 years (9.9% to 26.0%).
Younger age at type 2 diabetes onset linked to higher risk of subsequent dementia
An analysis of a prospective cohort study in the U.K. found that developing type 2 diabetes before age 70 years was associated with greater likelihood of having dementia, and dementia risk increased with longer duration of diabetes.
MKSAP quiz: Declining kidney function
This month's quiz asks readers to evaluate a 67-year-old woman with type 2 diabetes, diabetic nephropathy, and retinopathy, and choose a medication management strategy.
Spotlight on GLP-1 receptor agonists and the lungs
The theory that glucagon-like peptide-1 (GLP-1) receptor agonists may have beneficial effects on the lungs gained support from recent analyses of patients with asthma, chronic lower respiratory diseases, and all types of respiratory diseases.
SGLT2 inhibitors reduce all-cause mortality
A recent meta-analysis found lowered mortality risk with sodium-glucose cotransporter-2 (SGLT2) inhibitors, and an ACP Journal Club commentary added that other trials have shown beneficial effects of the drug class on kidney function in patients with type 2 diabetes.
In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM
A industry-funded trial found improved glucose control in men randomized to testosterone injections, but some of its claims were exaggerated, and routine use of testosterone therapy to prevent or reverse type 2 diabetes is not recommended, an ACP Journal Club commentary said.
Racial, economic disparities found in use of SGLT2 inhibitors
Although use of sodium-glucose cotransporter-2 (SGLT2) inhibitors rose overall between 2015 and 2019, patients who were Black, Asian, female, or with lower household income had lower rates of prescriptions for the drug class than others with type 2 diabetes.
Webinar will provide tips on using CGM to improve type 2 diabetes management
An ACP webinar on June 15 will teach primary care clinicians how to identify good candidates for continuous glucose monitoring (CGM) and how to use CGM data to empower patients to improve their type 2 diabetes self-management.